ClinicalTrials.gg
RecruitingNCT07505277Updated Apr 1, 2026

Study of the Effects of Food Formulations Containing Antioxidants, Prebiotic Fibers, and Oat Beta-glucans in Individuals at Risk of Metabolic Syndrome

An interventional study of Mediterranean diet and Mediterranean diet + functional foods in Metabolic Syndrome, sponsored by Dr. Schär AG / SPA. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 95 studies in Metabolic Syndrome with a site in Italy — 16 open to participants now, 18 under way, none of them phase 3. Metabolic Syndrome · Italy.

Planned enrollment
48th of 62
40 · median 71
Started
2026
with 2 others
No phase
38 of 95
8 open now
Primary completion
2027-02
later than 12 of 17 live
Registered
92nd of 95
by date

Among the 95 studies in Metabolic Syndrome with a site in Italy, this one is the 48th largest by planned enrollment of the 62 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 with no phase, reaches primary completion later than 12 of the 17 other live ones, and was the 92nd registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

16 of the 95 studies in Metabolic Syndrome with a site in Italy are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Metabolic Syndrome with a site in Italy, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate whether introducing specific functional foods into the diet of individuals at risk of developing metabolic syndrome leads to improvements in key metabolic and oxidative health parameters.

The main questions it aims to answer are:

Does the consumption of these functional foods reduce post-prandial glycemia? Does daily intake of these formulations improve other health indicators such as body weight, body composition, lipid profile, and oxidative metabolomic markers?

The functional food formulations used in this study include:

A blend of multifunctional ingredients derived from apple and grape by-products Added prebiotic fibers (inulin) Oat β-glucans Omega-3 fatty acids

Participants will:

Consume the assigned functional food formulations daily Attend regular clinic visits for physiological measurements and blood tests Undergo assessments of body composition, serum lipids, and serum metabolomics

Primary Study Objective:

Variation in post-prandial glycemia

Secondary Objectives:

Reduction in BMI Changes in body composition Changes in serum lipid profile Changes in serum oxidative-related metabolomics

03

Conditions studied

  • Metabolic Syndrome

Browse trials for

Keywords

  • Metabolic Syndrome
  • Functional foods
  • Nutritional intervantion
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 60 years
  • Individuals who do not have metabolic syndrome
  • Presence of abdominal circumference >94 cm for men or >80 cm for women, or a (BMI) between 25 and 34.9 kg/m², and at least two of the following parameters:
  • Impaired glucose tolerance (IGT) (≥100 mg/dL), or borderline hypertension (systolic 120-139 mmHg, diastolic 80-90 mmHg), or mild hypercholesterolemia (200-239 mg/dL)
  • Absence of any long-term pharmacological treatment for diabetes, hypertension, dyslipidemia, hyperuricemia, or other chronic conditions

Exclusion criteria

Exclusion Criteria:

  • Individuals with metabolic syndrome
  • Continuous pharmacological treatments for dysmetabolic conditions
  • \<18.5 kg/m² or >35 kg/m²
  • (HbA1c) > 6%
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Pre-post design

    Standard diet for 8 weeks, followed by the introduction of functional foods for an additional 8 weeks

    Other: Mediterranean diet and Mediterranean diet + functional foods

Interventions

  • OtherMediterranean diet and Mediterranean diet + functional foods

    1. PHASE: Mediterranean diet for 8 weeks 2. PHASE: Mediterranean diet + functional foods for 8 weeks

06

What researchers measure

Primary outcomes

  1. Changes in postprandial glycemia

    Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8

Secondary outcomes

  1. Changes in BMI

    Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8

  2. Changes in body composition

    Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8

  3. Changes in serum lipid profile

    Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8

  4. Changes in serum oxidative related metabolomics

    Time frame: PHASE 1: from baseline to week 8; PHASE 2: from baseline to week 8

07

Study locations

1 of 1 sites recruiting
  • Bonvicini Clinic
    Bolzano, Bolzano 39100, Italy
    Recruiting
08

References and documents

Publications

  • Andrea Pichler, Serena Foria, Martina Magni, Veronica Marin, Manuel Pramsohler, Gaetano Cardone, Peter Robatscher, Silvano Ciani, Ombretta Polenghi, Virna Lucia Cerne, Michael Oberhuber, Comparative analysis of health-promoting nutrients in oat cultivars from Alpine production versus commercial origin, Journal of Cereal Science, Volume 127, 2026, 104351, ISSN 0733-5210, https://doi.org/10.1016/j.jcs.2025.104351. (https://www.sciencedirect.com/science/article/pii/S0733521025002504)
  • Cardone G, Magni M, Marin V, Pichler A, Zatelli D, Robatscher P, Polenghi O, Cerne VL, Oberhuber M, Ciani S. Upcycling of By-Products from Autochthonous Red Grapes and Commercial Apples as Ingredients in Baked Goods: A Comprehensive Study from Processing to Consumer Consumption. Antioxidants (Basel). 2025 Jun 27;14(7):798. doi: 10.3390/antiox14070798. PubMed 40722902 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 50 industry-sponsored interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2026
First posted
Apr 1, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Jun 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505277
Lead sponsor
Dr. Schär AG / SPA
Collaborators
Bonvicini Clinic
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Feb 1, 2026
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Prof. Lucio Lucchin
Contact
veronica.marin@drschaer.com
+39 0471 442700

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion